Compare AbbVie Inc (ABBV) vs Vanguard Total Bond Market Index Fund ETF (BND) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Vanguard Total Bond Market Index Fund ETF — how do they compare? AbbVie Inc trades at $253.95 (market cap $449.91B), while Vanguard Total Bond Market Index Fund ETF trades at $72.66. The key difference: AbbVie Inc pays a 2.72% dividend while Vanguard Total Bond Market Index Fund ETF pays none, and AbbVie Inc is trading nearer its 52-week high, Vanguard Total Bond Market Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | BND | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | — |
52-Week High | $261.07 | $75.17 |
52-Week Low | $184.85 | $72.45 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
BND trades at $72.85, down 0.36% with a bearish technical signal from moving averages. The ETF shows neutral oscillator readings with RSI at oversold levels. Recent dividend distributions of $0.24-$0.25 provide income appeal, while financial media highlights BND's role in diversified portfolios and compares it favorably against peers on yield and cost metrics.
The outlook remains cautious given the bearish technical setup and interest rate sensitivity. BND offers broad bond market exposure for income-focused investors, though duration risk persists if rates rise. Current levels may appeal to long-term investors seeking steady income with institutional quality diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Vanguard Total Bond Market Index Fund ETF
This index measures the performance of a wide spectrum of public, investment-grade, taxable, fixed income securities in the US, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities-all with maturities of more than 1 year. All of the fund's investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the index.
Read more on BND →
